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ABSTRACT: Individuals with Down syndrome (DS, trisomy 21) exhibit a pro-oxidative cellular environment as
well as mitochondrial dysfunction. Increased oxidative
stress may damage the mitochondrial DNA (mtDNA).
The coexistence of mtDNA variants in a cell or tissue
(i.e., heteroplasmy) may contribute to mitochondrial dysfunction. Given the evidence on mitochondrial dysfunction and the relatively high incidence of multiorganic
disorders associated with DS, we hypothesized that cardiac tissue from subjects with DS may exhibit higher frequencies of mtDNA variants in comparison to cardiac
tissue from donors without DS. This study documents
the analysis of mtDNA variants in heart tissue samples
from donors with (n = 12) and without DS (n = 33) using massively parallel sequencing. Contrary to the original
hypothesis, the study’s findings suggest that the cardiac
mitochondrial genomes from individuals with and without
DS exhibit many similarities in terms of (1) total number of mtDNA variants per sample, (2) the frequency of
mtDNA variants, (3) the type of mtDNA variants, and (4)
the patterns of distribution of mtDNA variants. In both
groups of samples, the mtDNA control region showed significantly more heteroplasmic variants in comparison to
the number of variants in protein- and RNA-coding genes
(P < 1.00×10−4 , ANOVA).
C 2016 Wiley Periodicals, Inc.
Hum Mutat 00:1–7, 2016. 

KEY WORDS: Down syndrome; trisomy 21; heteroplasmy; cardiac; mitochondrial variants; massively parallel
sequencing

Introduction
Mitochondria are organelles critical for various cellular functions including the synthesis of ATP by oxidative phosphorylation,
maintenance of cellular calcium homeostasis, and detoxification of
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reactive oxygen species (ROS) generated from cellular respiration
[Nicholls, 2002]. Each mitochondrion contains multiple copies of
mitochondrial DNA (mtDNA), and there are hundreds to thousands of mtDNA copies per cell [Ye et al., 2014]. Human mtDNA
is a double-stranded circle of 16,569 base pairs. The mitochondrial
genome contains a noncoding control region (CR), 13 genes encoding for proteins of the oxidative phosphorylation system, 22 tRNA
genes, and two rRNAs genes. Damage to mtDNA can result in mitochondrial dysfunction. Mitochondrial dysfunction contributes to a
number of metabolic and degenerative diseases, and is also involved
in cancer and ageing (Wallace, 2005). Metabolically active tissues
such as heart and brain are especially susceptible to the bioenergetic deficits resulting from mitochondrial dysfunction (Wallace
and Chalkia, 2013).
Individuals with Down syndrome (DS, trisomy 21) exhibit mitochondrial dysfunction (Arbuzova et al., 2002; Ogawa et al., 2002;
Roat et al., 2007; Infantino et al., 2011; Coskun and Busciglio, 2012).
Mitochondrial dysfunction has been associated with the etiology of
early-onset dementia in patients with DS. Higher frequency of mutations in mtDNA, specifically in the CR, and decreased mtDNA
copy numbers have been observed in brains of patients with DS and
dementia in comparison to age-matched controls (Coskun, et al.,
2010). The exact molecular events linking variation in mtDNA sequence to disease are not yet fully characterized (Dai, et al., 2012).
Some individuals with DS display signs and symptoms of premature ageing in specific body systems including the endocrine, musculoskeletal, immunological, and neurological systems. The cardiovascular system seems to be less affected by ageing in the DS setting,
for example, the incidence of hypertension and ischemic cardiac
disease is relatively low in adults with DS (Zigman, 2013). However, patients with acute leukemia and DS may be more susceptible
to the cardiotoxic effects of anticancer anthracycline drugs (Hefti
and Blanco, 2016). A recent study suggests that in myocardial tissue
from individuals with DS, the expression of certain anthracycline
metabolizing enzymes (i.e., AKR7A2) and mtDNA content are important variables in determining the cardiac synthesis of toxic drug
metabolites (Hoefer, et al., 2016). Increases in the frequency of specific mtDNA variants (i.e., heteroplasmy) in cardiac tissue may contribute to the development of cardiac dysfunction that does occur
in some cases with DS (Balli, et al., 2016; Vetrano, et al., 2016). Recently, we documented a nonsignificant 30% decrease in the levels of
cardiac mtDNA and a nonsignificant 30% increase in the frequency
of the “common” mtDNA4977 deletion in heart tissue samples from
donors with DS (n = 11) in comparison to samples from donors
without DS (n = 31). We noted that the trend toward decreased
mtDNA content in DS hearts seemed to be independent from the
donor’s age (Hefti, et al., 2016). Thus, and given both the evidence
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on mitochondrial dysfunction and the relatively high incidence of
multiorganic disorders associated with DS, we hypothesized that
cardiac tissue from subjects with DS may exhibit higher numbers
and frequencies of mtDNA variants in comparison to cardiac tissue from donors without DS (Hwang and Jea, 2013; Glasson, et al.,
2014; Head, et al., 2015). With the exception of data on mtDNA
heteroplasmy derived from brain tissue from subjects with DS and
a report on tissular heteroplasmy from Naue et al. (2015), there
is a noticeable paucity of reports describing the extent of mtDNA
heteroplasmy in most tissues (Coskun and Busciglio, 2012; Naue,
et al., 2015). This is especially true with regards to cardiac tissue
from subjects with DS.
Massively parallel sequencing is a robust, high-throughput technique that allows the accurate identification of heteroplasmic
mtDNA variants. This method was pioneered by Tang and Huang
(2010) for identifying mitochondrial heteroplasmy in 2010. The
analysis of mtDNA variants by massively parallel sequencing will
contribute to expand our understanding of the molecular bases underlying mitochondrial dysfunction in various clinical settings, including DS. In this study, massively parallel sequencing was applied
to the analysis and annotation of heteroplasmic mtDNA variants in
a collection of heart tissue samples from donors with and without
DS. These data provide the first insights into the extent of heteroplasmic mtDNA variation in the cardiac tissue of individuals with
DS.

Materials and Methods
Heart Samples
The Institutional Review Board at the University at Buffalo approved this research. Heart samples from donors with (n = 12) and
without DS (n = 33) were procured from The National Disease Research Interchange, The Cooperative Human Tissue Network, and
the National Institute of Child Health and Human Development
Brain and Tissue Bank. The postmortem to tissue recovery interval
was 10 hr. Samples (0.50–20 g, myocardium, left ventricle only)
were frozen immediately after recovery and stored in liquid nitrogen until further processing. The main demographics from donors
with and without DS are summarized in Suppl. Table S1. DS status (yes/no) and relevant diagnoses (when available) were obtained
from anonymous medical histories. Heart samples were processed
following standardized procedures to isolate total cardiac DNA as
described (Hefti, et al., 2016). Age matched groups (n = 10 for each
group) were utilized for some comparisons to minimize the potential confounding effect of age on mtDNA variation (mean ageNDS
= 46.50 years, SD = 22.40 vs. mean ageDS = 46.6, SD = 21.83, P = 0.99,
Student’s t-test) (Sevini, et al., 2014; Naue, et al., 2015).

Cardiac mtDNA Amplification
The entire mitochondrial genome was amplified in two fragments
using high-fidelity long-distance PCR (LD-PCR) with Takara LA
(Clontech, CA) as described by Tang and Huang (2010). Cardiac
mtDNA fragment 1 (9,289 bp in length) was amplified with the
following primers: forward 5 -AACCAAACCCCAAAGA CACC-3 ,
reverse 5 -GCCAATAATGACGTGAAAGTCC-3 . Cardiac mtDNA
fragment 2 (7,626 bp in length) was amplified with the following primers: forward 5 -TCCCACTCCT AAACACATCC-3 , reverse
5 -TTTATGGGGTGATGTGAGCC-3 . The LD-PCR amplification
conditions were as follows: 25 cycles at 94°C for 25 sec and 68°C for
16 min. PCR amplification products were analyzed by electrophore-
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sis on agarose gels and purified with suitable kits (Bio Basic, Ontario,
CA). DNA concentrations were determined with the PicoGreen
Assay (Invitrogen, Waltham, MA).

Massively Parallel Sequencing
cDNA libraries were prepared with Nextera sample preparation
kits (Illumina, San Diego, CA). The cDNA libraries were quantified
using a PicoGreen assay (Invitrogen) and Kapa qPCR library quantification kit (Kapa Biosystems, Wilmington, MA). Size and quality
of cDNA libraries were confirmed using an Agilent Bioanalyzer 2100
(Santa Clara, California) DNA high-sensitivity chip. The cDNA libraries were then pooled based on qPCR values. cDNA products
were sequenced in rapid mode on an Illumina HiSeq 2500 DNA
sequencing system at the University at Buffalo Genomics and Bioinformatics Core Facility (Buffalo, NY). The sequencing data were uploaded to GenBank (http://www.ncbi.nlm.nih.gov/genbank/). The
accession number for the data is SRP074312.

Sequencing Output Analysis
Paired sequence reads were demultiplexed using Illumina’s
bcl2fastq version 1.8.4. Reads were then mapped to the mitochondrial genome NC 012920.1 (version GI: 251831106) utilizing the
CLC Genomics Workbench version 8.0.1 alignment tool (Venlo, The
Netherlands). After mapping, reads underwent variant calling using
CLC Genomics Workbench (v8.0.1) requiring a minimum coverage
of 1,000X and a minimum frequency of 1.00×10–6 . An average of
7.50 million reads were mapped for each sample. Imported reference data from dbSNP was used to identify mitochondrial variants,
which were compiled into Microsoft Excel spreadsheets for further
analysis. Data on mtDNA variants were submitted to the MITOMAP database (www.mitomap.org). Diagnostic single-nucleotide
polymorphisms (SNPs) available on the MITOMAP database were
utilized to identify mtDNA haplogroups (Suppl. Table S1). Distributions and frequencies of heteroplasmic mtDNA variants were
mapped on a circular plot using the Circlize package in R.

Data Analysis
The mean number of heteroplasmic mtDNA variants present in
a locus was obtained from the average number of individual heteroplasmic variants present in the specified location from all samples
within the groups being considered. The frequency represents the
percentage of mitochondrial genomes that contain a specific variant. Mean frequency values present in a locus were obtained from
the average frequency of all heteroplasmic mtDNA variants present
in the specified location from all samples within the group. Frequency values were used to classify mtDNA variants after the application of a conservative 2% error rate (He, et al., 2010). mtDNA
variants exhibiting frequency values between 2% and 98% range
were considered heteroplasmic. The D’Agostino and Pearson omnibus tests were used to ascertain the normality of datasets. Twotailed Student’s t-test was used to compare the means of normally
distributed datasets, and the Mann-Whitney U test was used to
compare the means of non-normally distributed datasets. Correlation analyses were performed with Pearson’s product-moment test.
Analysis of variance (ANOVA) with post-hoc Turkey’s test was used
to compare mean number of variants and mean frequency. In all
cases, differences between means were considered to be significant at
P < 0.050.

There were 415 heteroplasmic mtDNA variants in the group of
heart samples from subjects without DS (12.57 heteroplasmic variants per sample). According to the NCBI dbSNP database, 89 of
the variants (21.44%) have been previously identified; however,
these variants have not yet been associated to a particular disease
state. Of the remaining mtDNA variants, 323 (77.83%) have not
yet been previously identified, and three (0.72%) were identified
as pathogenic or possibly pathogenic by NCBI dbSNP and MITOMAP databases. Specifically, the single-nucleotide variants (SNVs)
rs200145866:T>C (Ile165Thr), rs1599988:T>C (Tyr304His), and
rs28357980:A>G (Asn150Asp) have been associated with the pathogenesis of Leber’s optic neuropathy (Johns and Berman, 1991;
Yu-Wai-Man and Chinnery, 1993; Howell, et al., 1995). The frequency values of these potentially pathogenic mtDNA variants in
cardiac tissue were 97.25%, 95.97%, and 96.71%. There were 73 nonsynonymous SNVs in the group of samples from donors without
DS (mean = 2.21, SD = 1.41 nonsynonymous variants per sample).
Figure 1A compiles the distribution and frequency values of
mtDNA variants in 12 cardiac mitochondrial genomes from donors
with DS. The CR of mitochondrial genomes from individuals with
DS showed a relative increase in the density of variants in comparison to the other mtDNA regions (Fig. 1A). There was an area
of increased mtDNA variant density in MT-ND1, similar to the
NDS group. In general, heteroplasmic mtDNA variants were more
prevalent in the CR and protein coding regions.
There were 127 mtDNA variants in the group of heart tissue
samples from donors with DS (10.6 variants per sample). Twentynine variants (22.83%) were previously identified and are present
in the NCBI dbSNP database. These variants have not yet been
clinically associated with any disease state. Ninety-eight mtDNA
variants (77.16%) are currently unidentified and are not present in
the NCBI dbSNP database. There were no pathogenic or potentially
pathogenic mtDNA variants in the group of cardiac mitochondrial
genomes from individuals with DS. There were 25 nonsynonymous
heteroplasmic mtDNA variants, with an average of 2.08 (SD = 2.28)
nonsynonymous variants per sample in donors with DS.

Figure 1. A: Heteroplasmic mtDNA variants in cardiac tissue from
donors with and without DS. Rings 1 and 2 show the density of mtDNA
variants in tissue samples from donors with (red, n = 12) and without
DS (black, n = 33). Ring 3 shows the frequency of the corresponding
variants. The closer the circle is to the outer region of ring 3, the higher
the frequency of the variant. Ring 4 indicates the genes or regions of the
mitochondrial genome. B: Map of heteroplasmic mtDNA variant density
and frequency in heart samples from age-matched groups of donors
with and without DS (n = 10 for both groups).

Results
Cardiac mtDNA Variants in Samples from Donors with and
Without DS
Figure 1A shows the distribution and frequency of heteroplasmic
mtDNA variants in heart samples from donors with (red, n = 12) and
without (black, n = 33) DS. The CR and the MT-ND1 gene showed
relative increases in the density of mtDNA variants in comparisons
to other loci in the mitochondrial genome (Fig. 1A). The frequency
values associated with the heteroplasmic variants in the CR and
the MT-ND1 gene were highly variable and ranged from 2.03% to
95.96% for MT-ND1 and 2.01% to 97.80% for the CR.

Cardiac mtDNA Variants in Samples from Age-Matched
Donors with and Without DS
Aging affects mtDNA heteroplasmy in tissues (Sevini, et al.,
2014; Naue, et al., 2015). Thus, we compared cardiac heteroplasmic mtDNA variants in a subset of age-matched samples to control
for this potential confounder. Figure 1B shows the distribution and
frequency of heteroplasmic mtDNA variants in age-matched heart
samples from donors with (red) and without (black) DS. The distribution of variants and corresponding frequency values across the
mitochondrial genomes from donors with and without DS were
similar (Fig. 1A and B).
Overall, the number of mtDNA variants per gene were similar
between age-matched samples from donors with and without DS
(Suppl. Table S2; Table 1). In age-matched samples from donors
with DS, there was a trend toward a decrease in the mean frequency (freq%) of mtDNA variants in the hypervariable control
region (HCR) versus the regulatory control region (RCR) (mean
freq%DS-HCR = 11.54, SD = 18.62 vs. mean freq%DS-RCR = 30.45,
SD = 7.32, P = 0.070, Mann-Whitney U test). This trend was
not apparent in the group of age-matched samples from donors
without DS (mean freq%Non-DS-HCR = 35.97, SD = 42.94 vs. mean
freq%Non-DS-RCR = 30.33, SD = 7.28, P = 0.54, Mann-Whitney U test).
Samples from donors with and without DS also showed similar
HUMAN MUTATION, Vol. 00, No. 0, 1–7, 2016
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Table 1. Comparison of Number and Frequency of Heteroplasmic mtDNA Variants in Control Region, Protein Coding Region, and RNA
Coding Region in Heart Samples from Age-Matched Donors with and Without DS (n = 10 Samples for Both Groups)
Down syndrome(mean ± SD)
Control region variants

Mean variant number
Mean variant frequency (freq%)
Mean variant number
Mean variant frequency (freq%)
Mean variant number
Mean variant frequency (freq%)

Protein coding variants
RNA coding variants

a

7.20
31.06
2.30
25.68
0.80
16.17

±
±
±
±
±
±

Non-Down syndrome(mean ± SD)

3.85
7.23
1.55
30.62
0.92
30.01

8.60
33.62
3.20
18.61
0.80
16.95

±
±
±
±
±
±

2.46
10.38
1.40
17.61
0.63
30.91

P valuea
0.40
0.54
0.11
0.68
0.77
0.85

Student’s t-test used for comparisons of normally distributed data; Mann-Whitney U test used for non-normally distributed data.

DS: 78.26%). The number of nonsynonymous variants per sample
was similar between both groups (Table 3).

Number of protein coding variants
in cardiac mtDNA
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Figure 2. Linear regression analysis of the number of protein coding variants in mtDNA versus age in heart samples from age-matched
donors with and without DS (n = 10 samples for both groups, non-DS
= 0.57, P = 0.080 vs. rDS = −0.27, P = 0.46, Pearson’s Product-Moment
correlation). Each symbol represents the total number of protein coding
variants per sample.

distributions of mtDNA variants along the binding motifs for essential mitochondrial transcription factors (Suppl. Table S3).
There was a trend toward a positive correlation between the
total number of protein coding mtDNA variants and age in the
group of age-matched samples from donors without DS (r = 0.57,
P = 0.080, Pearson’s Product-Moment correlation). The trend was
not evident in the group of age-matched samples from donors with
DS (r = –0.27, P = 0.46, Pearson’s Product-Moment correlation; Fig.
2). There were no significant correlations between either the number or frequency of heteroplasmic mtDNA variants and age in both
age-matched groups (Table 2).
There were no significant differences in RNA or protein coding
nonsynonymous, synonymous, or SNV number or frequency between the age-matched groups (Table 3). There were no statistically
significant differences in the number of RNA or protein coding insertions and deletions (INDELs) between the age-matched groups
(Table 3). The coding INDELs observed in both groups ranged from
1 to 9 bp in length.
The mean number of mtDNA variants in the CR, protein, and
RNA coding regions were significantly different in both groups of
age-matched samples (ANOVANon-DS and ANOVADS , P < 1.00×10–4 ;
Fig. 3). The number of heteroplasmic mtDNA variants located in
RNA coding regions was lower than the number of variants in protein coding and CR, respectively (Fig. 3). In terms of protein coding
mtDNA variants, both groups of samples showed a preponderance
of nonsynonymous over synonymous variants (non-DS: 84.38%;
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Massively parallel sequencing allows the examination of tissular
mtDNA variants with a very high depth of coverage (>1,000×).
With the exception of data on mtDNA variants derived from brain
tissue from subjects with DS, there is a noticeable paucity of reports
describing the extent of mtDNA heteroplasmy in most tissues, including cardiac tissue, from subjects with DS. This is noteworthy
because several lines of evidence suggest that widespread mitochondrial dysfunction contributes to many of the pathophysiological
alterations associated with DS (Coskun and Busciglio, 2012; Pagano
and Castello, 2012). Despite these pathophysiological alterations,
the current life expectancy for individuals with DS has reached the
sixth decade of life with some individuals (10%) living up to
70 years of age; this increase is attributed to improved medical care
for those with DS (Brown, et al., 2001; Head, et al., 2015). In this
study, massively parallel sequencing was applied to the analysis of
mtDNA heteroplasmy in a collection of heart tissue samples representative of the current life span for persons with DS. For comparison, mtDNA heteroplasmy was analyzed in a group of samples from
subjects without DS, which included an age-matched subgroup.
Our initial hypothesis postulated that the cardiac mitochondrial
genomes from subjects with and without DS would show differences
in the number and/or distribution of mtDNA variants. However,
the study’s main findings suggest that the cardiac mitochondrial
genomes from individuals with and without DS exhibit many similarities in terms of (1) total number of mtDNA variants per sample, (2) the frequency of mtDNA variants, (3) the type of mtDNA
variants, and (4) the patterns of distribution of mtDNA variants
(Fig. 1; Suppl. Table S2). At first glance, these findings are surprising
given that DS status has been associated with increased intracellular
generation of damaging ROS combined with less effective mtDNA
repair mechanisms (Druzhyna, et al., 1998; Roat, et al., 2007). However, studies that considered noncardiac cells (e.g., DS astrocytes and
lymphocytes) showed that trisomic samples displayed an “adaptive
response” to the chronic increase in oxidative stress. This “adaptive
response” results in an overall decrease in mitochondrial function in
order to minimize the production of ROS and reduce further damage to the mtDNA (Perluigi and Butterfield, 2012; Helguera, et al.,
2013). It is possible that this “adaptive response” is present in the
myocardial tissue of individuals with DS through the entire lifespan.
The result would be the preservation of the cardiac mitochondrial
genome, as manifested by levels of mtDNA variation comparable
to the non-DS setting, at the expense of relative decreases in mitochondrial function. Further comparative studies in cardiac tissue
samples and/or cellular models (e.g., induced pluripotent stem cell
derived cardiomyocytes) would be needed to determine whether the

Table 2. Correlation Analysis of Heteroplasmic mtDNA Variant Number and Frequency with Age in Age-Matched Donors with and
Without DS (n = 10 Samples for Both Groups)∗
Down syndrome
r
Control region variants versus age
Protein coding variants versus age
RNA coding variants versus age

∗

Mean variant number
Mean variant frequency (freq%)
Mean variant number
Mean variant frequency (freq%)
Mean variant number
Mean variant frequency (freq%)

Non-Down syndrome

P value

0.44

r

0.20
0.68
0.46
0.79
0.37
0.072

–0.15
–0.27

0.10
0.32
–0.77

0.25
–0.016

0.57
0.16
0.042
0.20

P value
0.48
0.96
0.080
0.66
0.48
0.70

Pearson’s Product-Moment correlation analysis.

Table 3. Comparison of SNVs, Coding INDELs, and Nonsynonymous Heteroplasmic mtDNA Variants in Heart Samples from Age-Matched
Donors with and Without DS (n = 10 Samples for Both Groups)
Down syndrome(mean ± SD)
Single-nucleotide variants (SNVs)b
Coding insertions and deletions (INDELs)
Nonsynonymous SNVs

a
b

Mean variant number
Mean variant frequency (freq%)
Mean variant number
Mean variant frequency (freq%)
Mean variant number
Mean variant frequency (freq%)

6.00
24.50
0.70
6.19
1.30
8.37

±
±
±
±
±
±

Non-Down syndrome(mean ± SD)

P valuea

±

0.25
0.32
0.17
0.12
0.18
0.40

2.94
17.90
1.34
15.11
1.25
11.74

7.60
32.54
1.20
15.74
2.10
12.92

±
±
±
±
±

3.50
21.33
1.03
21.56
1.37
15.44

Student’s t-test used for comparisons of normally distributed data; Mann-Whitney U test used for non-normally distributed data.
Total SNV in coding and noncoding regions.

Figure 3. Mean number of heteroplasmic mtDNA variants (protein
coding, RNA coding, and control regions) in heart samples from agematched donors with and without DS (n = 10 samples for both groups).
Each bar represents the mean ± SD. ∗ P < 0.050 (one-way ANOVA with
post-hoc Turkey test).

control of cardiac mtDNA heteroplasmy in the trisomic setting is
associated with compensatory changes in mitochondrial function.
This study documented relatively high numbers of mtDNA variants in cardiac tissue (Tables 1 and 2). Cardiac tissue is mostly
composed of postmitotic cells, and the majority of the cardiomyocytes in an individual will not be replaced during a normal lifespan
(Bergmann, et al., 2009). Thus, the low turnover of cardiac tissue
may result in the accumulation and propagation of certain heteroplasmic mtDNA variants (Taylor and Turnbull, 2005; Tuppen,
et al., 2010). Heart tissue samples from donors with and without
DS showed a wide range of heteroplasmy (i.e., >2%–<98%), and
mtDNA variants with frequency values near the upper limit may be
in fact homoplasmic mtDNA variants. In general, there was good
agreement between the donor’s ethnicity as listed in the available
clinical reports (i.e., “white” or European American and “black” or
African American) and corresponding mtDNA haplogroups from

Africa and Europe (Suppl. Table S1). However, in the absence of
paired samples of maternal DNA, it was not possible to: (1) estimate
the fraction of haplotype associated variants, and (2) estimate the
fractions of germline and “de novo” mtDNA variants (He, et al.,
2010).
In both groups of samples, the variants with the highest degree
of heteroplasmy tended to concentrate in the CR and the MT-ND1
gene. The CR is critical for transcription and regulation of the mitochondrial genome. The CR is the most variable region in the
mitochondrial genome. Naue et al. (2015) examined mtDNA variants in the CR in nine different tissues from 100 individuals, and
found similar numbers of mitochondrial point heteroplasmies in
heart and brain, whereas skeletal muscle and liver exhibited the
highest number of heteroplasmies. Variation in the CR may affect mtDNA copy number (i.e., mtDNA content) (Coskun, et al.,
2010). In a previous study involving this set of heart samples, we
documented a nonsignificant 30% (P = 0.65) decrease in mtDNA
content in samples with DS in comparison to samples without DS
(Hefti, et al., 2016). Coskun et al. (2010) examined the frequency
of mtDNA CR mutations in samples from cerebral frontal cortices
from age-matched subjects with and without DS, and found that
mean mutation frequencies were similar between both groups. In
agreement, heart tissue samples from subjects with and without
DS showed similar levels of heteroplasmy when considering the entire CR as well as distinct regulatory elements within the CR that
are involved in the replication of mtDNA (Fig. 1A and B; Suppl.
Table S3).
Age-matched groups of cardiac samples from donors with and
without DS displayed similar distribution and mean frequency values of heteroplasmic mtDNA variants in RNA and protein coding
genes (Fig. 1B). Both groups displayed reduced numbers of RNA
variants, as well as reduced numbers of protein coding variants
in comparison to the number of variants in the CR (Fig. 3). The
majority of the protein coding variants in both groups were nonsynonymous, therefore, potentially damaging. In general, increased
numbers and frequencies of mtDNA variants in protein coding and
HUMAN MUTATION, Vol. 00, No. 0, 1–7, 2016
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tRNA coding regions are more likely to be pathogenic compared
with other mtDNA regions (Ye, et al., 2014). This pattern of regional variation in cardiac mtDNA is consistent with the recent
conclusions made by Ye et al. (2014) after analyzing massively parallel sequencing data from the 1000 Genomes Project. The authors
proposed that a purifying selection process may reduce the prevalence and accumulation of potentially pathogenic mtDNA variants
in specific mitochondrial loci such as tRNAs and protein coding
genes to avoid the propagation of mitochondrial dysfunction (Ye,
et al., 2014).
There are limitations in the present study. The sample size was
limited due to the scarcity of good quality cardiac tissue samples
from donors with DS; this common problem impacts research
on many of the issues concerning the pathobiology of DS (OsterGranite, et al., 2011). Thus, it was not possible to detect relatively
subtle differences in mtDNA frequencies (Suppl. Table S4). The lack
of matched maternal tissue samples precluded determining whether
the cardiac mtDNA variants were either inherited or acquired (i.e.,
somatic) mtDNA variants. Thus, the observed frequency values may
not fully reflect the impact of DS status on somatic mtDNA variants. Furthermore, the reliance on cadaveric tissue samples from
donors with various clinical histories makes it almost impossible
to control for potential clinical confounders. Furthermore, the resulting cross-sectional nature of the comparisons should be considered when evaluating the potential impact of age and/or other
putative covariables on heteroplasmic mtDNA frequencies (Sevini,
et al., 2014). Although massively parallel sequencing is a powerful
method for the analysis of mtDNA variants in human tissues, it
often cannot detect large deletions in mtDNA. For example, the
“common” mtDNA 4,977 bp deletion cannot be reliably detected by
massively parallel sequencing because of its relatively low frequency
in cardiac tissue (DS% frequency mtDNA 4977 deletion : 0.0086 ± 0.0166, nonDS% frequency mtDNA 4977 deletion : 0.0066 ± 0.0124; P = 0.514) (Tang and
Huang, 2010; Hefti, et al., 2016).
The results from this study suggest similar distribution of heteroplasmic mtDNA variants in hearts from individuals with and
without DS. The data presented in this study offer a glimpse into
the patterns of heteroplasmic mtDNA variants in cardiac tissue from
donors with DS. These data may advance our understanding of tissular mtDNA variation and its potential relation to the complex
pathobiology of DS.
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